Dr. Long Jun Dai

Zhen-Xing Zhang, Li-Xue Guan, Kun Zhang, Shouxian Wang, Pei-Cheng Cao, Yong-He Wang,     Zhe Wang, Long-Jun Dai: Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biology International. 31:645-648, 2007.

Download paper

Abstract This study concerns the cytogenetic stability of in vitro human bone marrow-derived mesenchymal stem cells (MSCs) in primary culture and after passaging. Bone marrow samples were collected from seven brain malfunction patients involved in autologous MSC transplantation trials. Chromosome preparations from primary MSC cultures and after 3 passages were analyzed by conventional staining and G-banding techniques. All MSCs showed normal diploid karyotypes, 46 XY or 46 XX, without aneuploidy or polyploidy; chromosome structural abnormalities were not detected. The results indicate that the in vitro cultured MSCs retained normal cytogenetics before being transplanted back into the patients.

Z-X Zhang, L-X Guan, K Zhang, Q Zhang, L-J Dai: A combined procedure to deliver  autologous mesenchymal stromal cells to patients with traumatic brain injury.  Cytotherapy 10:134-139, 2008.

Download Paper

Abstract There is increasing evidence of therapeutic benefits from bone marrow (BM)-derived mesenchymal stromal cells (MSC) in various animal models with neurologic disorders. It is of great interest to apply the approach to clinical patients, i.e. to take the investigations from laboratory bench to the patient’s bedside. This clinical trial was performed to assess the safety and feasibility of a combined procedure to deliver autologous MSC to patients with traumatic brain injury.

Long-Jun Dai, Hong-Ying Li, Li-Xue Guan, Gordon Ritchie, Jeff X. Zhou: The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Research 2:16-25, 2009.

Download Paper

Abstract Hepatic cirrhosis is the end-stage of chronic liver diseases. The majority of patients with hepatic cirrhosis die from life-threatening complications occurring at their earlier ages. Liver transplantation has been the most effective treatment for these patients. Since liver transplantation is critically limited by the shortage of available donor livers, searching for an effective alternative therapy has attracted great interest in preclinical studies. The transplantation of autologous bone marrow-derived mesenchymal stem cells holds great potential for treating hepatic cirrhosis. Mesenchymal stem cells can differentiate to hepatocytes, stimulate the regeneration of endogenous parenchymal cells, and enhance fibrous matrix degradation. Experimental and clinical studies have shown promising beneficial effects. This review is intended to translate the bench study results to the patients’ bedside. The potential interventions of mesenchymal stem cells on cirrhosis are illustrated in terms of the cellular and molecular mechanisms of hepatic fibrogenesis.